-
Risk of Cancer in RA Patients Treated with Disease-Modifying Drugs; A Different Kind of Fish Story; Antidepressants and Auto Accidents
-
There has long been an appreciation of the risk of cognitive decline associated with chemotherapy but questions remain about the magnitude and duration of the observed deficits. In this meta-analysis of studies that included neuropsychological assessments at a minimum of 6 months after completion of breast cancer chemotherapy, definite but small deficits were found for both verbal and visuospatial capabilities.
-
Dementia and benzodiazepines; effectiveness of omega-3 fatty acid and Ginkgo biloba supplements; and FDA actions.
-
Three common medications amitripty-line, duloxetine, and pregabalin all appear equally efficacious in treating neuropathic pain from diabetic neuropathy.
-
In a prospectively followed cohort of obese, non-diabetic men and women from Sweden, individuals who underwent bariatric surgery had an 83% reduction in the risk of developing type 2 diabetes over 15 years of follow-up.
-
A modified recombinant human granulocyte colony-stimulating factor (G-CSF) has been approved by the FDA.
-
Nightly melatonin improved objective and subjective sleep quality in a small number of patients who were taking beta-blockers for hypertension.
-
The FDA has approved an ethyl ester of eicosapentaenoic acid (EPA) to treat hypertriglyceridemia. It is the second drug in this class after Lovaza, which contains esters of both EPA and DHA (docosahexaenoic acid). Icosapent ethyl is marketed by Amarin Pharmaceuticals, a Dublin, Ireland-based company, as Vascepa.
-
Scenario: The lead II rhythm strip shown above was observed on telemetry. Is the patient in atrial flutter?
-
